SRCM
ABBV icon

Swift Run Capital Management’s AbbVie ABBV Stock Holding History

Swift Run Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$311K Buy
2,900
+500
+21% +$48K 0.6% 35
2020
Q3 		$210K Hold
2,400
– – 0.42% 43
2020
Q2 		$236K Buy
+2,400
New +$211K 0.39% 45

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Swift Run Capital Management's ABBV Position: Q4 2020 in Review

Swift Run Capital Management increased its AbbVie (ABBV) stake by 21% in Q4 2020, buying an estimated $48K and bringing the position to 2,900 shares worth $311K. The position accounts for 0.6% of the portfolio, ranked #35.

Swift Run Capital Management first reported a position in ABBV in Q2 2020 and has held it in 3 quarters since. 2,597 funds tracked by Wall St. Rank hold ABBV as of Q4 2020.

  • Swift Run Capital Management held 2,900 shares of AbbVie worth $311K as of Q4 2020.
  • Swift Run Capital Management bought 500 AbbVie shares in Q4 2020, an estimated $48K.
  • AbbVie made up 0.6% of Swift Run Capital Management's portfolio in Q4 2020, its #35 holding.
  • Swift Run Capital Management first reported a position in AbbVie in Q2 2020 and has held it in 3 quarters since.
  • 2,597 funds tracked by Wall St. Rank held AbbVie as of Q4 2020.

Based on Swift Run Capital Management's 13F filing for Q4 2020, filed 2 Feb 2021.